日本心力衰竭的特征和结果:基于医院的行政数据库分析
Yasuhisa Ono1, Kazuhiro Yoneda1, Naoki Okuyama2
1Nippon Boehringer Ingelheim, Tokyo, Japan.
ESC heart failure
|September 3, 2024
概括
这项研究分析了日本心力衰竭 (HF) 患者的情况,发现在住院期间越来越多地规定了指导方针导向疗法. 提供了关于高频患者特征和结果的真实世界数据,以告知临床决策.
科学领域:
- 心脏病学和心血管疾病.
- 医疗保健服务研究 医疗服务研究
- 流行病学 流行病学
背景情况:
- 有限的流行病学和结果数据存在于日本心力衰竭 (HF) 患者的左心室喷射分数 (LVEF) 分层.
- 了解HF患者的个人资料和治疗模式对于改善日本的临床决策和医疗资源分配至关重要.
研究的目的:
- 提供关于日本住院心力衰竭患者的特征,治疗模式和结果的真实数据,由LVEF分类.
- 分析不同HF类别的药物使用趋势,住院费用,退院后再住院和死亡率.
主要方法:
- 一项非干预性数据库研究,利用日本志愿医院 (VHJ) 组织17家医院的行政索赔和电子医疗记录.
- 包括2017年4月至2020年3月期间被诊断患有HF的7212名住院患者,根据LVEF分类为具有保存EF的HF (HFpEF),轻度减少EF的HF (HFmrEF) 和减少EF的HF (HFrEF).
- 评估基线特征,入院前诊断,处方药,住院时间,治疗费用,以及对住院后结果的探索性分析.
主要成果:
- 这项研究包括7212名患者,44.1%的HFpEF,17.7%的HFmrEF和38.1%的HFrEF.
- 药物使用,包括β阻塞剂,ACE抑制剂和ARBs,在住院期间显著增加,在出院时观察到各类HF类别的不同处方模式.
- 平均住院时间为22.2天,HFrEF患者的治疗费用和整体住院费用最高. 大约有21%的患者再次住院,8.7%的患者在随访期间死亡.
结论:
- 高频率类别的分布与现有数据保持一致,排放药物反映了对指导方针治疗的高度遵守.
- 这项研究为日本的高频管理提供了有价值的现实洞察力,支持未来的临床实践和政策制定.
- 这些发现强调了需要继续研究和优化治疗策略,以满足日本多样化的HF患者群体的需求.
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:22Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
01:26Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545